Millions of people have found a lifeline in the illicit cannabis economy in these past decades, but traditional cannabis farmers in the South are confronted with huge obstacles to participating in the emerging legal markets. The rapidly expanding legal cannabis markets for medical and adult use are increasingly captured by corporate businesses. Cultivation is more and more shifting from the South to the North, from small farmers to big companies, and from outdoor to indoor, with negative impacts on sustainable development goals.
The Transnational Institute (TNI) issued their first policy brief which argues that it is vital that the socio-economic needs and rights of traditional cannabis producers are not overlooked and that ‘no-one is left behind’ in this historic transition.
To read the brief, please follow this link>>>.
The new review published by the Archives of Industrial Hygiene and Toxicology, takes a quick look at the current legal framework in the European Union which regulates cannabis use and cultivation for medicinal purposes. The document was prepared by Slovene Metoda Lipnik-Štangelj from the Faculty of Medicine, Department of Pharmacology and Experimental Toxicology, Ljubljana and Barbara Razinger from the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia.
From the abstract
The discovery of the endocannabinoid system has raised public interest in the medicinal use of cannabis, phytocannabinoids, and synthetic cannabinoids, which has always been closely regulated due to their psychotropic effects and potential abuse. The review takes a quick look at the current legal framework in the European Union, which regulates cannabis use and cultivation for medicinal purposes in line with the United Nations Conventions on the production, trade, and use of cannabis, phytocannabinoids, and synthetic cannabinoids. And while the EU legislation precisely defines requirements and marketing authorisation procedures for medicinal products for all EU member states, there is no common regulatory framework for magistral and officinal preparations containing cannabinoids, as they are exempt from marketing authorisation. Instead, their regulation is left to each member state, and it is quite uneven at this point, mainly due to cultural and historical differences between the countries, leading to different access to non-authorised medicinal products. Therefore, to meet great public interest, harmonised approaches on cannabinoid-containing products without marketing authorisation would be welcome to level the playing field in the EU.
To read/download the review, follow this link>>>.